---
title: Practical guidelines for the management of adverse events of the T cell engager
  bispecific tebentafusp
date: '2023-08-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37595494/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230819181039&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Tebentafusp is a new T cell receptor bispecific fusion protein and the
  first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01)
  metastatic uveal melanoma, with a proven benefit in overall survival versus the
  investigator's choice. As a first-in-class therapeutic option, this Immune mobilising
  monoclonal T cell receptor Against Cancer (ImmTAC) is associated with a new adverse
  event (AE) profile. Based on clinical experience, a national expert group ...
disable_comments: true
---
Tebentafusp is a new T cell receptor bispecific fusion protein and the first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01) metastatic uveal melanoma, with a proven benefit in overall survival versus the investigator's choice. As a first-in-class therapeutic option, this Immune mobilising monoclonal T cell receptor Against Cancer (ImmTAC) is associated with a new adverse event (AE) profile. Based on clinical experience, a national expert group ...